15 recruiting. 15 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 15 | Recruiting 15 |
| Phase 2 | 1 | Recruiting 1 |
Follow Vision Disorders: new trials by email Literature Review of Vision Disorders trials Research Report on Vision Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome Placebo, NPI-001 - Retinitis Pigmentosa (RP), Usher Syndrome | Phase 3 | Recruiting | Nacuity Pharmaceuticals, Inc. | 80 | 2026-10-23 | 2026-11-10 |
| Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research Privosegtor, Methylprednisolone, Placebo - Optic Neuritis | Phase 3 | Recruiting | Oculis | 210 | 2026-05-28 | 2026-08-14 |
| Efficacy and Safety Study of Ixoberogene Soroparvovec (Ixo-vec) in Participants With Neovascular Age-related Macular Degeneration (AQUARIUS) Ixo-vec, Aflibercept - Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD | Phase 3 | Recruiting | Adverum Biotechnologies, Inc. | 534 | 2026-03-16 | 2026-09-24 |
| A Randomized, Parallel-arm, Double Blind, Placebo-controlled Study to Assess the Efficacy of Fampridine for Patients With Spinocerebellar Ataxia SCA27B Caused by a GAA Expansion in the FGF14 Gene Fampridine 10 mg prolonged-release tablet (per os), Placebo (tablets per os) - Spinocerebellar Ataxia 27B (SCA27B) | Phase 3 | Recruiting | Assistance Publique - Hôpitaux de Paris | 70 | 2025-10-21 | 2025-12-10 |
| OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity 0.75% Phentolamine Ophthalmic Solution, Placebo - Vision Loss Night, Vision Disorders | Phase 3 | Recruiting | Opus Genetics, Inc | 580 | 2025-09-02 | 2026-10-14 |
| Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION) sepofarsen, Placebo IVT - Leber Congenital Amaurosis 10, Blindness | Phase 3 | Recruiting | Laboratoires Thea | 32 | 2025-06-04 | 2026-10-21 |
| Dichoptic Treatment for Amblyopia in Children 8 to 12 Years of Age Vivid Vision, Luminopia, Optical Correction - Amblyopia | Phase 3 | Recruiting | Jaeb Center for Health Research | 252 | 2024-10-22 | 2026-11-02 |
| Dichoptic Treatment for Amblyopia in Children 4 to 7 Years of Age Luminopia, Eye Patch - Amblyopia | Phase 3 | Recruiting | Jaeb Center for Health Research | 238 | 2024-07-11 | 2026-11-02 |
| Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy Faricimab, fluocinolone acetonide - Radiation Retinopathy, Visual Impairment | Phase 3 | Recruiting | Jaeb Center for Health Research | 600 | 2023-11-21 | 2026-10-23 |
| Paclitaxel Coated Balloon for the Treatment of Chronic bEnigN sTricture- Bowel GIE Medical ProTractX3 TTS DCB, Control - Bowel; Stricture | Phase 3 | Recruiting | GIE Medical | 171 | 2023-11-01 | 2025-06-25 |
| Alcohol Use Disorder and Cannabidiol Cannabidiol, Placebo - Alcohol Use Disorder | Phase 2 / Phase 3 | Recruiting | University of Colorado, Denver | 180 | 2023-04-30 | 2026-06-15 |
| Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects Rimegepant, Placebo - Migraine | Phase 3 | Recruiting | Pfizer | 640 | 2022-02-28 | 2026-10-14 |
| Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine Rimegepant (PF-07899801) - Acute Treatment of Migraine | Phase 3 | Recruiting | Pfizer | 600 | 2021-04-28 | 2026-10-27 |
| Randomized Study in Children and Adolescents With Migraine: Acute Treatment Rimegepant/BHV3000, Matching placebo - Pediatric Migraine | Phase 3 | Recruiting | Pfizer | 2100 | 2021-01-15 | 2026-10-27 |
| A Randomized Trial to Evaluate Sequential vs Simultaneous Patching Patching, Glasses - Amblyopia | Phase 3 | Recruiting | Jaeb Center for Health Research | 544 | 2020-12-08 | 2026-02-11 |
Amblyopia (3) · Hyperacusis (3) · Migraine Disorders (3) · Nausea (3) · Photophobia (3) · Blindness (2) · Color Vision Defects (2) · Eye Diseases (2) · Alcoholism (1) · Ataxia (1) · Constriction, Pathologic (1) · Diplopia (1) · Eye Abnormalities (1) · Eye Diseases, Hereditary (1)
Nervous System Diseases (15) · Pathological Conditions, Signs and Symptoms (15) · Signs and Symptoms (15) · Neurologic Manifestations (14) · Sensation Disorders (14) · Eye Diseases (13) · Brain Diseases (6) · Central Nervous System Diseases (6) · Ear Diseases (4) · Hearing Disorders (4) · Otorhinolaryngologic Diseases (4) · Eye Diseases, Hereditary (3) · Headache Disorders (3) · Headache Disorders, Primary (3)
rimegepant sulfate (3) · 4-Aminopyridine (1) · Cannabidiol (1) · Eyeglasses (1) · Fluocinolone Acetonide (1) · Methylprednisolone (1) · aflibercept (1) · faricimab (1)
Jaeb Center for Health Research (4) · Pfizer (3) · Adverum Biotechnologies, Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · GIE Medical (1) · Laboratoires Thea (1) · Nacuity Pharmaceuticals, Inc. (1) · Oculis (1) · Opus Genetics, Inc (1) · University of Colorado, Denver (1)
United States (14) · Spain (4) · Canada (3) · France (3) · Poland (3) · Japan (2) · United Kingdom (2) · Australia (1) · Belgium (1) · Brazil (1) · China (1) · Germany (1) · Italy (1) · Mexico (1) · Netherlands (1)
Adam Turpcu, PhD (1) · Aparna Raghuram, OD, PhD (1) · Benajmin G Jastrzembski, MD (1) · Kammi Gunton, MD (1) · Kent Hutchison, PhD (1) · Marjean T Kulp, OD (1) · Michael Gray (1) · Robert Henderson, MS (1) · Vivian Manh (1)
2UG1EY011751 (3), R01AA029606 (1), UG1EY014231 (1)